EcoDrugPlus

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSOKIG00005020467
Gene Symbol: CHRM4
1 Cross references
178 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSOKIG00005010084
Gene Symbol: CHRM5
3 Cross references
188 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOKIG00005027762
Gene Symbol: CHRNA3
3 Cross references
196 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOKIG00005016978
Gene Symbol: CHRNA3
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSOKIG00005044316
Gene Symbol: CHRNA4
1 Cross references
136 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSOKIG00005012820
Gene Symbol: CHRNB2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSOKIG00005044209
Gene Symbol: CHRNB2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSOKIG00005027747
Gene Symbol: CHRNB4
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSOKIG00005016968
Gene Symbol: CHRNB4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSOKIG00005011822
Gene Symbol: CHRM2A
1 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSOKIG00005001776
Gene Symbol: CHRM5A
1 Cross references
189 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSOKIG00005032922
Gene Symbol: CHRM5B
1 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).